Drug Trial Radar · NCT03255070
A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)
Last checked: Nov 19, 2026Latest source record: Feb 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
106
Actual
Start
Mar 20, 2018
Primary completion
Sep 13, 2023
Study completion Oct 18, 2023
Sponsor
- Lead sponsor
- Ambrx, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 21, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This 2-part, Phase 1, open-label study will determine the recommended Phase 2 dose (RP2D) of ARX788 in subjects with advanced HER2 positive cancers and will assess the safety and anticancer activity in breast, gastric and other advanced HER2 positive solid tumors.
Conditions
- Breast Neoplasms
- Gastric Neoplasm
- Solid Tumors
Interventions
ARX788Drug
An antibody drug conjugate
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of subjects experiencing adverse events, frequency and seriousness of treatment emergent adverse events (TEAEs)Time frame: Day 1 through 30 days after last dose
- Phase 1b: Objective response rate (ORR: complete response + partial response) per imaging assessment based on RECIST version 1.1.Time frame: 36 months
Locations
12 sites in 2 countries. Site status is shown where the registry gives one.
USC Norris Cancer Hospital
Los Angeles, California
UCLA Hematology-Oncology
Santa Monica, California
Washington University School of Medicine
St Louis, Missouri
Cleveland Clinic
Cleveland, Ohio
Baylor Sammons Cancer Center
Dallas, Texas
Research Site
East Albury, New South Wales, Australia
Research Site
North Sydney, New South Wales, Australia
Mater Misericordiae Limited
South Brisbane, Queensland, Australia
Princess Alexandria Hospital
Woolloongabba, Queensland, Australia
Monash Health
Clayton, Victoria, Australia
Research Site
Frankston, Victoria, Australia
Research Site
Nedlands, Western Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.